Oric Pharmaceuticals (ORIC) Stock News

ORIC Pharmaceuticals (Nasdaq: ORIC) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company secured $244 million in financing, including a $125 million private placement and $119 million from ATM issuances, extending its cash runway into 2H 2028.

Key highlights include promising Phase 1b trial results for ORIC-944 in prostate cancer treatment, showing a 59% PSA50 response rate and 24% PSA90 response rate. The company is advancing both ORIC-944 and ORIC-114 (enozertinib) towards potential Phase 3 trials in 2026. As part of a strategic restructuring, ORIC is reducing its discovery research investment, resulting in a 20% workforce reduction.

ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has announced the granting of inducement equity awards to two new non-executive employees. The grants, approved under Nasdaq Rule 5635(c)(4), include 35,000 non-qualified stock options and 5,800 restricted stock units.

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made through the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee.

ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has granted equity inducement awards to a new non-executive employee. The grants, approved on July 1, 2025, include 9,000 non-qualified stock options and 1,600 restricted stock units.

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).

ORIC Pharmaceuticals announced the granting of inducement equity awards to three new non-executive employees who joined in May 2025. The grants, approved under Nasdaq Rule 5635(c)(4), include 39,100 non-qualified stock options and 6,500 restricted stock units. The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. The options' exercise price matches ORIC's closing stock price on June 2, 2025. These grants, made through the company's 2022 Inducement Equity Incentive Plan, were approved by ORIC's Compensation Committee as employment inducements.

ORIC Pharmaceuticals (NASDAQ: ORIC) has secured a $125 million private placement financing through the sale of approximately 19.2 million shares at $6.50 per share, representing an 18% premium to its 10-day trailing VWAP. The financing, led by SR One with participation from notable investors including Point72, Viking Global Investors, and others, is expected to close on May 29, 2025.

The company will issue common stock and pre-funded warrants with an exercise price of $0.0001 per share. The proceeds, combined with existing cash reserves, are expected to fund operations into the second half of 2027, including through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in prostate cancer.

ORIC Pharmaceuticals (NASDAQ: ORIC) reported promising preliminary data from its Phase 1b trial of ORIC-944 in combination with AR inhibitors for treating metastatic castration-resistant prostate cancer (mCRPC). Key highlights include:

- 59% PSA50 response rate (47% confirmed) and 24% PSA90 response rate (all confirmed) across all dose levels

- Safety profile shows majority of adverse events were Grade 1 or 2, with diarrhea being the most common side effect in 53% of patients

The company secured a $125 million private placement financing, extending cash runway into 2H 2027. ORIC plans to complete Phase 1b dose exploration by mid-2025, followed by dose optimization in 2H 2025, and aims to initiate its first global Phase 3 registrational trial in 1H 2026.

ORIC Pharmaceuticals (NASDAQ: ORIC), a clinical stage oncology company, has announced its participation in two major investor conferences in June 2025. The company will engage in fireside chats at:

- The Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET

- The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET

Webcasts of both discussions will be accessible through ORIC's investor relations website and will remain available for replay for 90 days after the events.

ORIC Pharmaceuticals (NASDAQ: ORIC) has announced an upcoming presentation of initial data from their Phase 1b trial of ORIC-944. The trial evaluates the combination of ORIC-944 with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC).

The presentation will take place during a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. Investors can access the presentation through phone participation with pre-registration or via webcast through the company's website. The webcast recording will be available for 90 days after the presentation.

ORIC Pharmaceuticals reported Q1 2025 financial results and operational updates. The company highlighted $223.8 million in cash and investments, expected to fund operations into 2027. Key developments include: (1) Presented preclinical data for ORIC-944 showing synergistic activity with AR inhibitors in prostate cancer, (2) Established clinical trial collaboration with Johnson & Johnson for ORIC-114 in combination with amivantamab for NSCLC treatment, (3) Plans to initiate Phase 3 trials for ORIC-944 in mCRPC in 1H 2026 and ORIC-114 in NSCLC later in 2026. Financial results showed R&D expenses of $24.6 million (up from $22.0M YoY) and G&A expenses of $8.1 million (up from $7.0M YoY). The company expects five data readouts across both clinical programs over the next 15 months.